See more : The North West Company Inc. (NWC.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Sana Biotechnology, Inc. (SANA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sana Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- M8 Sustainable Limited (M8S.AX) Income Statement Analysis – Financial Results
- O2Micro International Limited (OIIM) Income Statement Analysis – Financial Results
- Franklin Electric Co., Inc. (FELE) Income Statement Analysis – Financial Results
- Slack Technologies Inc (8S0.DE) Income Statement Analysis – Financial Results
- Westag AG (WUG3.DE) Income Statement Analysis – Financial Results
Sana Biotechnology, Inc. (SANA)
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| Gross Profit | -30.87M | -27.73M | -17.91M | -10.17M | -3.92M | -1.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.64M | 201.00M | 306.50M | 257.88M | 119.38M | 4.01M |
| General & Administrative | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 8.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.21M |
| SG&A | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 4.21M |
| Other Expenses | 0.00 | -674.00K | 305.00K | 97.00K | -29.00K | 0.00 |
| Operating Expenses | 294.94M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Cost & Expenses | 325.81M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Interest Income | 9.94M | 3.76M | 676.00K | 747.00K | 2.86M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| EBITDA | -252.39M | -256.94M | -356.91M | -287.03M | -138.90M | -13.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -326.90M | -272.56M | -356.91M | -286.15M | -141.15M | -8.22M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 43.65M | 3.09M | 981.00K | 844.00K | 2.83M | -5.03M |
| Income Before Tax | -283.26M | -269.48M | -355.93M | -285.31M | -138.33M | -13.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.09M | -11.75M | -6.67M | -7.55M | 0.00 |
| Net Income | -283.26M | -266.39M | -344.18M | -278.64M | -130.78M | -13.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| EPS Diluted | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| Weighted Avg Shares Out | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Weighted Avg Shares Out (Dil) | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle
SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Source: https://incomestatements.info
Category: Stock Reports